GLP ObserverRx cash prices

GLP-1 price changes, newest first

Verified Subscribe via RSS

The GLP-1 price-change log is a dated record of every self-pay price change we track for Zepbound, Wegovy, the Wegovy pill, Ozempic, Mounjaro and Foundayo. Each entry is a manufacturer announcement or a change we observed on a live price page, with its source. The same log feeds our charts and the RSS feed.

A green paper strip folded into a descending staircase on navy-ruled grid paper
  1. observed Observed: Novo’s $199 intro price now runs through December 31, 2026; Wegovy HD 7.2 mg is $399; Wegovy pill $149–$299 by dose. [1]
  2. observed Observed: NovoCare notice that Saxenda will be discontinued, with last shipments to wholesalers in late January 2027 (not a safety or quality issue). [2]
  3. observed Observed: Novo says Rybelsus is being replaced by the Ozempic pill; the Rybelsus savings-offer page now opens the Ozempic offer. [3]
  4. ▼ price cut Observed: Foundayo 2.5 mg temporarily $149 (regular $199) and 5.5 mg $199 (regular $299) through December 31, 2026. [4]
  5. observed Observed: Zepbound late-refill (regular) prices are now $499 for 7.5 mg and $699 for 10–15 mg, versus $599–$1,049 in Lilly’s Dec 2025 release. [5]
  6. new Medicare GLP-1 Bridge starts: eligible Part D enrollees pay $50 a month for Wegovy, Foundayo and the Zepbound KwikPen, through December 31, 2027. [6]
  7. new Foundayo (orforglipron) pill launches; self-pay from $149 a month at the lowest dose, $25 with commercial coverage. [7]
  8. observed Novo Nordisk announces it will cut the list price of Wegovy, Ozempic and Rybelsus to $675 a month from January 1, 2027; self-pay prices are not affected. [8]
  9. new Zepbound KwikPen (four doses, one month) launches on LillyDirect at the same self-pay prices as vials, from $299. [9]
  10. ▼ price cut Zepbound vials cut to $299 (2.5 mg), $399 (5 mg) and $449 (7.5–15 mg with on-time refills). [10]
  11. ▼ price cut Wegovy and Ozempic self-pay cut from $499 to $349 (Ozempic 2 mg stays $499); new-patient intro price of $199 for the first two fills of 0.25 and 0.5 mg. [11]
  12. observed The $499 Wegovy offer extends to retail pharmacies via the savings offer, replacing a $650-a-month offer. [12]
  13. ▼ price cut NovoCare Pharmacy launches with all Wegovy pen doses at $499 a month for cash-paying patients. [13]
  14. ▼ price cut Zepbound 2.5 mg vial cut to $349 and 5 mg to $499; new 7.5 mg and 10 mg vials at $499 with on-time refills (regular $599 / $699). [14]
  15. new Lilly launches Zepbound single-dose vials on LillyDirect: 2.5 mg $399, 5 mg $549 per four-week supply. [15]

Sources

Every price above links to one of these pages. We loaded each one and saved a copy on the date shown.

  1. Wegovy savings offer and self-pay prices (pen, HD pen and pill) . Novo Nordisk (NovoCare). Checked .
    https://www.novocare.com/obesity/products/wegovy/savings-offer.html
  2. Saxenda cost, coverage and savings resources (discontinuation notice) . Novo Nordisk (NovoCare). Checked .
    https://www.novocare.com/obesity/products/saxenda.html
  3. RYBELSUS savings and support resources (Rybelsus is being replaced by Ozempic pill) . Novo Nordisk (NovoCare). Checked .
    https://www.novocare.com/diabetes/products/rybelsus.html
  4. Foundayo coverage and savings (self-pay terms) . Eli Lilly and Company. Checked .
    https://foundayo.lilly.com/coverage-savings
  5. Zepbound on LillyDirect (vial and KwikPen self-pay prices) . Eli Lilly and Company. Checked .
    https://www.lilly.com/lillydirect/zepbound
  6. What to Know About the BALANCE Model for GLP-1s in Medicare and Medicaid and the Medicare GLP-1 Bridge . KFF, published May 11, 2026. Checked .
    https://www.kff.org/medicare/what-to-know-about-the-balance-model-for-glp-1s-in-medicare-and-medicaid/
  7. Foundayo (orforglipron), Lilly’s new oral GLP-1 pill for weight loss, now available in the U.S. . Eli Lilly and Company, published Apr 9, 2026. Checked .
    https://investor.lilly.com/news-releases/news-release-details/foundayotm-orforglipron-lillys-new-oral-glp-1-pill-weight-loss
  8. Novo Nordisk lowers US list price of Wegovy, Ozempic and Rybelsus to $675 a month from January 1, 2027 . Novo Nordisk U.S., published Feb 24, 2026. Checked .
    https://www.novonordisk-us.com/media/press-releases/novo-nordisk-lowers-wegovy-ozempic-list-price.html
  9. Zepbound (tirzepatide) now available in multi-dose KwikPen . Eli Lilly and Company, published Feb 23, 2026. Checked .
    https://investor.lilly.com/news-releases/news-release-details/zepbound-tirzepatide-most-prescribed-weight-management
  10. Lilly lowers the price of Zepbound (tirzepatide) single-dose vials . Eli Lilly and Company, published Dec 1, 2025. Checked .
    https://investor.lilly.com/news-releases/news-release-details/lilly-lowers-price-zepboundr-tirzepatide-single-dose-vials
  11. Novo Nordisk launches introductory self-pay offer for Wegovy and Ozempic for $199 per month . Novo Nordisk (via PR Newswire), published Nov 17, 2025. Checked .
    https://www.prnewswire.com/news-releases/novo-nordisk-launches-introductory-self-pay-offer-for-wegovy-and-ozempic-for-199-per-month-302617100.html
  12. Novo Nordisk expands Wegovy $499-per-month offering to additional cash-paying patients . Novo Nordisk (via PR Newswire), published Mar 24, 2025. Checked .
    https://www.prnewswire.com/news-releases/novo-nordisk-expands-wegovy-499-per-month-offering-to-additional-cash-paying-patients-via-the-wegovy-savings-offer-302408528.html
  13. Novo Nordisk introduces NovoCare Pharmacy, lowering cost of all doses of Wegovy to $499 per month . Novo Nordisk (via PR Newswire), published Mar 5, 2025. Checked .
    https://www.prnewswire.com/news-releases/novo-nordisk-introduces-novocare-pharmacy-lowering-cost-of-all-doses-of-fda-approved-wegovy-semaglutide-to-499-per-month-and-offering-easy-home-delivery-for-cash-paying-patients-302392874.html
  14. Lilly launches additional Zepbound vial doses and offers new savings for self-pay patients . Eli Lilly and Company, published Feb 25, 2025. Checked .
    https://investor.lilly.com/news-releases/news-release-details/lilly-launches-additional-zepbound-vial-doses-and-offers-new
  15. Lilly releases Zepbound (tirzepatide) single-dose vials, expanding supply and access for adults living with obesity . Eli Lilly and Company, published Aug 27, 2024. Checked .
    https://investor.lilly.com/news-releases/news-release-details/lilly-releases-zepboundr-tirzepatide-single-dose-vials-expanding